Portable Multiplexed LATE-PCR Influenza Test

便携式多重 LATE-PCR 流感检测

基本信息

  • 批准号:
    7452748
  • 负责人:
  • 金额:
    $ 140.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The project will develop a decaplex assay to detect varieties of the Category C Priority Pathogen, influenza, listed in Table 1, within 30 minutes of taking a raw patient sample. The subtypes that are detected are all highly pathogenic strains of H5 and H7, which are classed as Select Agents by the USDA. The assay will be developed for the 6-color Bio-Seeqll, a portable, battery operable, thermocycler / fluorometer designed with automated sample preparation for ease of use in the point-of-care clinical market. The requested support will accelerate the development of the human diagnostic version of the influenza assay, and provides a vehicle to gain access to government expertise and resources (e.g., influenza strains). The following activities are planned to advance assay development through pre-clinical validation: 1. Construct a decaplex RT-LATE PCR assay to detect of any of the clinically relevant influenza varieties (including highly pathogenic varieties), in a single tube through iterative interaction modeling and empirical verification. 2. Investigate factors affecting assay performance: Optimize RNA extraction / purification protocols for influenza samples, and lyophilized RT-PCR reagent formulation, for best influenza assay sensitivity, specificity, and robustness in the integrated cartridge (USPD). 3. Perform pre-clinical validation of assay, including comparability testing against available, validated PCR assays. Table 1. Assay targets and subtype identification.Influenza TypeHA SubtypeNA SubtypeHigh vs. Low PathogenicityAH1N1, N2, other H3N1, N2, other H5N1, N2, otherYes H7N1, N2, otherYesBType B HA Relevance: This assay will enable faster, more effective diagnosis of influenza to detect outbreaks (especially of highly pathogenic varieties), reduce unneeded antibiotic use, reduce hospital stays, and enable more effective use of neuraminidase inhibitors, preserving Strategic National Stockpile of drugs for response to pandemic influenza.
描述(由申请人提供): 该项目将开发一种十重检测试剂盒,用于在采集原始患者样本后30分钟内检测表1所列的C类优先病原体流感。检测到的亚型均为H5和H7高致病性毒株,被美国农业部归类为选择因子。该检测试剂盒将针对6色Bio-Seeqll开发,这是一种便携式、电池可操作的热循环仪/荧光计,设计有自动样品制备功能,便于在床旁临床市场使用。所要求的支持将加快流感检测的人类诊断版本的开发,并提供获得政府专业知识和资源的途径(例如,流感病毒株)。计划开展以下活动,以通过临床前验证推进检测试剂盒开发:1.通过迭代相互作用建模和经验验证,构建一种十重RT-LATE PCR检测试剂盒,在单管中检测任何临床相关流感品种(包括高致病性品种)。2.研究影响检测性能的因素:优化流感样本的RNA提取/纯化方案和冻干RT-PCR试剂配方,以获得最佳流感检测灵敏度、特异性和集成检测盒(USPD)的稳健性。3.对检测试剂盒进行临床前验证,包括与现有经验证的PCR检测试剂盒进行可比性检测。 表1. 检测目标和亚型鉴定。流感类型HA亚型NA亚型高与低致病性AH 1 N1、N2、其他 H3 N1、N2、其他 H5 N1、N2、其他 H7 N1、N2、其他是B型B HA 相关性:这种检测方法将能够更快、更有效地诊断流感,以检测疫情(特别是高致病性品种),减少不必要的抗生素使用,减少住院时间,并能够更有效地使用神经氨酸酶抑制剂,保护国家战略药物储备,以应对大流行性流感。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barry E Boyes其他文献

Barry E Boyes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barry E Boyes', 18)}}的其他基金

High Resolution Superficially Porous Materials for Native Protein Separations
用于天然蛋白质分离的高分辨率表面多孔材料
  • 批准号:
    10255623
  • 财政年份:
    2021
  • 资助金额:
    $ 140.95万
  • 项目类别:
Improved Protein Separations with Superficially Porous Particles
使用表面多孔颗粒改进蛋白质分离
  • 批准号:
    8978832
  • 财政年份:
    2015
  • 资助金额:
    $ 140.95万
  • 项目类别:
Non-Spherical Particles for HPLC
用于 HPLC 的非球形颗粒
  • 批准号:
    8980294
  • 财政年份:
    2013
  • 资助金额:
    $ 140.95万
  • 项目类别:
Ellipsoid Particles for High Performance LC Separations
用于高性能 LC 分离的椭球颗粒
  • 批准号:
    8590657
  • 财政年份:
    2013
  • 资助金额:
    $ 140.95万
  • 项目类别:
Non-Spherical Particles for HPLC
用于 HPLC 的非球形颗粒
  • 批准号:
    9321117
  • 财政年份:
    2013
  • 资助金额:
    $ 140.95万
  • 项目类别:
Novel Materials and Methods for Separations of Glycopeptides and Glycans
用于分离糖肽和聚糖的新材料和方法
  • 批准号:
    8705538
  • 财政年份:
    2011
  • 资助金额:
    $ 140.95万
  • 项目类别:
Smaller Particle Fused-Core Silicas for Higher Performance Separations
较小颗粒的熔核二氧化硅可实现更高的分离性能
  • 批准号:
    8200510
  • 财政年份:
    2011
  • 资助金额:
    $ 140.95万
  • 项目类别:
Novel Materials and Methods for Separations of Glycopeptides and Glycans
用于分离糖肽和聚糖的新材料和方法
  • 批准号:
    8124341
  • 财政年份:
    2011
  • 资助金额:
    $ 140.95万
  • 项目类别:
Novel Materials and Methods for Separations of Glycopeptides and Glycans
用于分离糖肽和聚糖的新材料和方法
  • 批准号:
    8899355
  • 财政年份:
    2011
  • 资助金额:
    $ 140.95万
  • 项目类别:
Novel Materials and Methods for Separations of Glycopeptides and Glycans
用于分离糖肽和聚糖的新材料和方法
  • 批准号:
    8455999
  • 财政年份:
    2011
  • 资助金额:
    $ 140.95万
  • 项目类别:

相似海外基金

Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
  • 批准号:
    2902098
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Studentship
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
  • 批准号:
    EP/Z533026/1
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Research Grant
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
  • 批准号:
    BB/Y004035/1
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
  • 批准号:
    FT230100468
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
  • 批准号:
    EP/Y023528/1
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
  • 批准号:
    BB/Y007611/1
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
  • 批准号:
    MR/Y033809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
  • 批准号:
    494853
  • 财政年份:
    2023
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
  • 批准号:
    2884862
  • 财政年份:
    2023
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
  • 批准号:
    2904356
  • 财政年份:
    2023
  • 资助金额:
    $ 140.95万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了